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SUMMARY Monoclonal antibodies (mAbs) blocking the epidermal growth 
factor receptor (EGFR) pathway, such as cetuximab, have been widely used 
in recent years for the treatment of metastatic colorectal cancer (mCRC). The 
purpose of this study was to evaluate the profile of the side effects of cetux-
imab affecting the skin and its appendages. We gathered the medical records 
on skin-related toxicity in 46 patients treated with cetuximab for mCRC in the 
Department of Clinical Oncology, University Hospital in Krakow in 2009-2013. 
Skin toxicity was classified according to the National Cancer Institute Com-
mon Toxicity Criteria for Adverse Events version 4.0. The typical side effects of 
cetuximab were observed. The most common skin toxicity was an acne-like 
skin rash (80% of patients) and paronychia (20%). Other side effects were tri-
chomegaly, hypertrichosis, and allergic reactions. 
In view of high incidence of skin lesions during treatment with cetuximab, it 
is essential to observe patients carefully and to control the side effects dur-
ing therapy. Previous experience from clinical trials shows that in some cases 
proper care and prevention can improve the quality of the patients’ lives. 
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InTRodUCTIon
Colorectal cancer (CRC) is one of the most fre-
quently diagnosed malignancies in both men and 
women (1). One of the treatment options for meta-
static CRC (mCRC) is targeted therapy directed 
against the epidermal growth factor receptor (EGFR). 
This includes monoclonal antibodies (mAbs) – cetux-
imab and panitumumab. Cetuximab has shown its 
effectiveness in various lines of treatment of mCRC 
both in combination with cytotoxic chemotherapy 
and in monotherapy, mainly in patients with the wild-
type K-ras gene. Thus, mutation of K-ras is thought 
to be a negative predictive factor for the treatment 
with this mAb. Recently published combined analysis 
of pooled individual patient data from randomized 
phase III CRYSTAL (Cetuximab Combined with Irino-
tecan in First-Line Therapy for Metastatic Colorectal 
Cancer) and randomized phase II OPUS (Oxaliplatin 
and Cetuximab in First-Line Treatment of mCRC) clini-
cal trials demonstrated that addition of cetuximab 
to standard first-line chemotherapy in patients with 
K-ras wild-type mCRC significantly improved over-
all survival (OS) (hazard ratio [HR] 0.81; P=0.0062), 
progression-free survival (PFS) (HR 0.66; P<0.001) 
and overall response rate (ORR) (odds ratio 2.16; 
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P<0.0001) (2). The randomized CO.17 trial comparing 
cetuximab monotherapy versus best supportive care 
(BSC) in mCRC after failure of standard chemotherapy 
containing oxaliplatin, irinotecan, and 5-fluorouracil 
showed that cetuximab significantly improves OS, 
PFS and ORR (3). Finally, the BOND trial (4) demon-
strated that addition of cetuximab to irinotecan af-
ter failure of irinotecan-based chemotherapy in the 
previous setting significantly improved PFS and ORR 
compared to treatment with cetuximab alone. It is 
noteworthy that the efficacy of cetuximab shown in 
these trials was significantly higher among patients 
with prominent skin rash after cetuximab compared 
to patients without any or with mild skin reactions. 
Upregulated EGFR may cause uncontrolled 
changes in cell cycles. Overexpression of EGFR is also 
associated with increased metastatic potential and 
poorer prognosis in numerous malignancies (5,6). 
EGFR, also known as human epidermal growth fac-
tor receptor 1 (HER-1), is a member of HER family of 
receptors. They are transmembrane glycoproteins 
and consist of three main components: the extracel-
lular ligand binding domain, transmembrane part, 
and conserved intracellular tyrosine kinase (5). After 
binding of an extracellular domain to its ligand, the 
tyrosine kinase is activated and starts to phosphory-
late subsequent kinases on a signaling pathway. One 
of such networks is the mitogen-activated protein ki-
nase pathway (MAPK). The elements of the axis and 
the effects of its blockage by cetuximab are shown in 
Figure 1. As a result of the activation of the pathway, 
changes in cell behavior such as enhanced prolifera-
tion, transformation and impaired apoptosis, or dif-
ferentiation are seen. Moreover, signaling networks 
allow the signal to be amplified on its way from the 
cell membrane to the nucleus (7). Inhibition of the 
EGFR/ K-ras pathway in mCRC is connected with ad-
verse effects, among them: skin toxicity, diarrhea, hy-
pomagnesemia, and infusion reactions, as well as the 
most dangerous one – anaphylaxis. Taking into ac-
count the toxicity involving the skin and appendag-
es, the most frequent problems are: multiform rashes, 
especially acneiform, paronychia with pyogenic gran-
uloma, xerosis, eczema, hair changes, hypertrichosis, 
fissures, and hyperpigmentation (8). 
The purpose of this study was to evaluate the pro-
file of the side effects of cetuximab affecting the skin 
and its appendages. 
MATeRIAlS And MeThodS
Study group
A retrospective analysis of 46 patient histories was 
conducted (from October 2009 to March 2013). To be 
included in the analysis, a patient had to be treated us-
ing cetuximab in the Department of Clinical Oncology, 
University Hospital in Krakow, Poland. Additional inclu-
sion criteria were: age 18 and above, histologically con-
firmed diagnosis of CRC, presence of metastatic disease 
in diagnostic imaging (including computer tomography, 
magnetic resonance imaging, positron emission tomog-
raphy or bone scintigraphy), and lack of K-ras mutation. 
The exclusion criteria were: past or present concurrent 
malignancies, lack of consent to participate in the study, 
and previously diagnosed skin disease requiring chronic 
dermatological treatment.
Factors taken into consideration during the analy-
sis included: sociodemographic data, localization of 
primary cancer, clinical stage of the tumor according 
to the TNM staging system, type of treatment received, 
side effects related to cetuximab therapy and their in-
tensity, and the status of K-ras mutation. Skin toxicity 
was classified according to the National Cancer Insti-
tute Common Toxicity Criteria for Adverse Events ver-
sion 4.0 (CTCAE v 4.0) (9) as shown in Table 1.
Additionally, after receiving the patient’s permis-
sion, photographic documentation of the skin chang-
es was made. 
Statistical evaluation
Statistical analysis was conducted using comput-
er software Statistica 11.0 PL by StatSoft Poland (li-
censed to the Jagiellonian University Medical College, 
Poland). Descriptive statistics (range, mean, standard 
deviation, percentage distribution) were used. 
Student’s t-test was used when comparing quanti-
tative variables, and the Mann-Whitney test was used 
Figure 1. eGFR signaling axis and the effects of ce-
tuximab blockage (7).
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in the absence of a normal distribution of factors. Chi-
squared test was used when comparing qualitative vari-
ables, and the R Spearman test was applied for examin-
ing the correlation between quantitative variables. The 
results were presented using odds ratios (OR).
 A P-value <0.05 was taken to indicate significance. 
Ethical approval
The protocol of this study was approved by the 
Jagiellonian University Medical College Ethical Com-
mittee (registry number KB/254/B/2011). The study 
was performed in accordance with the ethical stan-
dards laid down in the 1964 Declaration of Helsinki 
and its later amendments.
ReSUlTS
Forty-six patients were included in the study. The 
population consisted of 12 women and 34 men; the 
median age was 55.4 years. The demographic distri-
bution is shown in Table 2.
All the patients were treated with cetuximab as 
a palliative therapy. Cetuximab was administered in 
a standard dose – 400 mg/m2 in a first dose and 250 
mg/m2 in each subsequent dose. 
The most commonly encountered adverse event, 
in both cetuximab in monotherapy and connected 
with chemotherapy, was an acne-like skin rash (ob-
served in 80% of patients, n=37), predominantly on 
the head and upper torso (59.5%, n=22 and 37.8%, 
n=14). Multiform rashes occurred mainly in the G2 
stage (51.4%, n=19) according to CTCAE v 4.0 (9). In 
  Table 1. Grades of chosen skin-related side effects according to CTCAE v. 4.0 (9)
Grade
Adverse event 1 2 3 4 5
Acneiform rash Lesions on < 10% 
of BSA.  






Lesions on > 30% of 
BSA. 




Lesions on any 








Paronychia Edema or erythema 
of the nail fold, 
cuticle disruption.
Edema or erythema of 
the nail fold with pain, 
discharge or nail plate 
separation, affecting 
instrumental ADL*.
Oral or localized 
intervention indicated.





hypertichosis Longer and thicker 
hair which the 




Longer and thicker hair 
on exposed area of the 
body. Frequent shaving 
or destructive methods 




Pruritus Mild or localized. 
Topical intervention 
needed.
Intense or widespread. 
Intermittent. Skin 






Intense or widespread. 
Constant. 
Limiting self care ADL 
or sleep. 




ADL – Activities of daily living
BSA – Body surface area
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*In some cases patients had more than one localization of metastatic disease.
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8.1% (n=3) they occurred in the G3 stage. However, 
all these patients completed chemotherapy treat-
ment of over 30 cetuximab doses. The rash was char-
acterized by a typical clinical course. Usually, after 2-4 
weeks a typical papulopustular rash could be seen. 
Changes were resolved by crusting. In some cases, in 
areas where lesions occurred, persistent dry skin, ery-
thema, or telangiectases could be observed. 
Another manifestation of cetuximab cutaneous 
toxicity was paronychial cracking starting typically 
2-3 months after initiation of the therapy. These le-
sions occurred either on the fingers or toes and were 
reported in 20% (n=9) of patients. Because of the 
development of G3 toxicity (according to CTCAE v. 
4.0) (9) one patient stopped cetuximab therapy. Less 
common side effects such as hypertrichosis and itch-
ing were observed in individual patients.
In 3 patients (6.5%) severe anaphylactic reactions 
to cetuximab developed and manifested as erythe-
ma, sweating, dyspnea, tachycardia, and hypoten-
sion. The treatment was discontinued. In our study, 
serum sickness appeared in one case. There were no 
treatment-related deaths. 
The median duration of treatment was 17 weeks 
(range 1 to 64). There were several chemotherapy pro-
tocol types: cetuximab in monotherapy or in combina-
tion with chemotherapy based on irinotecan, oxaliplat-
in, or capecytabine. Regardless of cetuximab treatment 
type, the progressive diseases (PD, based on imaginary 
studies or symptomatic progression) were principal 
reasons for cessation of treatment (80.4%, n=37). 
Figure 2. The typical course of a rash.
a) Papulopustular rash
b) Papulopustular rash with crusts


















Site of primary cancer
Rectum
Sigmoid colon
Rectum + sigmoid colon


































































Reason for treatment ending 
Progression
Intolerance (including allergic reactions)





























Table 2. Baseline demographic, disease and che-
motherapy characteristics
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Because of skin toxicity, the treatment was tem-
porary interrupted in four patients and ended in the 
one above-mentioned case. 
In our study there was no statistically significant 
association between the presence of a rash (no rash 
vs. any rash) and factors such as gender, age (>=55 
years old vs. <55), location of the primary tumor (rec-
tum vs. any other part of the colon), and number (>1 
vs. >=1) and location (liver vs. other places) of metas-
tases. 
dISCUSSIon
Targeted therapy is becoming an increasingly 
popular treatment option for cancer. One of advan-
tages of targeted agents is decreased risk of severe 
systemic side effects compared to cytotoxic agents. 
It is worth noting that adverse effects, while less dan-
gerous, are common and should be treated early. In 
many cases, proper care and prevention allow the 
quality of patient’s life to be improved (10). In this 
study, a cetuximab-dependent skin toxicity profile 
was described. Our results are generally consistent 
with the data presented in other studies (Table 3). 
The most common skin manifestation in the ana-
lyzed population was an acneiform eruption – 80%. 
Figure 2 shows the typical clinical course of the rash 
(a-d). Rash is the most frequently mentioned side ef-
fect during cetuximab therapy. In the literature, the 
fluctuation in the incidence oscillates from 52 to 92% 
(3,11-15). The main mechanism of acne-like rash is 
not fully understood. The blockage of EGFR both by 
monoclonal antibodies and EGFR-specific tyrosine 
inhibitors may result in similar skin toxicity (16). The 
EGFR is expressed in the basal epidermis layer and 
is indicated as an important factor in survival, motil-
ity and differentiation of keratinocytes (17). This can 
explain skin toxicity occurring during treatment with 
cetuximab, but does not clarify the acneiform nature 
of this eruption. The expression of EGFR on sebocytes 
seems to play a role in the localization of the rash (18). 
The body areas most often affected by comedonal and 
papulopustular lesions are rich in sebaceous glands, 
although the rash is histologically different from that 
present in acne vulgaris (8,19). In our patients, the 
head and upper torso were most frequently involved, 
which is consistent with the literature data concern-
ing mAbs directed against EGFR (20). The rash in our 
Figure 3. Periungueal changes.





















86 82.9 88.6 92 52 69.8
Grade 1 no data no data 39.6 55 (G1+G2) no data 48.3
Grade 2 no data no data 37.2 no data 44.8
Grade 3 18 4.9 11.8 26 (G3+G4) 12 10.3
Grade 4 no data no data 0 no data 0
Allergic reaction 
(G3) 
5 7.5 2.8 7 no data 6.9
Periungueal lesions 12 16.5 no data 32 no data 7
hipertrichosis no data no data no data no data no data 4.7
Figure 4. Trichomegaly.
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patients was usually mild to moderate (G1 in 27%, G2 
in 51.4%), which is consistent with the results pub-
lished in the above-mentioned studies (3,11-15). Se-
vere skin toxicity in Grade 3 occurred less commonly; 
however, in one of our patients, treatment was ter-
minated due to lesions on the top of the fingers, and 
four patients had administration of cetuximab tem-
porarily discontinued because of its toxicity. 
Canadian Treatment Recommendations advise 
topical clindamycin and steroids as a treatment for 
mild and severe skin rash. These agents reduce in-
flammation which has been connected with EGFR 
inhibition (21). The occurrence of moderate or severe 
skin toxicity may demand the use of oral tetracycline 
antibiotics. These agents are characterized by matrix 
metalloproteinase inhibition which results in anti-in-
flammatory properties. When duration of skin lesions 
is longer than 1-2 weeks despite treatment, or if other 
severe symptoms, such as necrosis or petechial or 
purpural lesions occur, referral to a dermatologist is 
advised (10).
Other recommendations for therapy with mAbs 
in the Skin Toxicity Evaluation Protocol with Panitu-
mumab (STEPP) , are based on topical corticosteroid 
hydrocortisone 1% and semisynthetic tetracycline 
analog doxycycline a moisturizer and sunscreen used 
in prevention of skin toxicities starting from the 1st 
to 6th week of the therapy with mAb (22). This treat-
ment, also used for the side effects of cetuximab, is a 
result of four main alterations caused by mAbs direct-
ed against EGFR: skin inflammation, bacterial super-
infection, dry skin, and skin sensitivity to ultraviolet 
radiation (22). 
Patients treated with cetuximab can develop dry, 
scaly, itchy skin, located especially at the earlier lo-
calization of the acneiform eruption (23). Excessive 
dryness of the skin can cause eczema and painful, 
bleeding fissures (19). Fissures which develop on the 
fingertips and toes make it difficult to perform daily 
activities. Abnormal skin dryness caused by cetux-
imab can be explained by the role of EGFR in reduc-
tion of the epidermis permeability (24). For primary 
prophilaxis of these changes, patients should be 
informed about the necessity of sun protection and 
of avoiding activities and products which could dry 
their skin (10). Emolients should be used in treating 
fissured skin (25).   
In our study, periungueal changes were observed 
in 20% of the patients – more often than in the lit-
erature where paronychia, painful inflammation of 
a fingernail or toenail fold, occurs in 10% to 15% of 
patients treated with cetuximab (16,26) (Figure 3). 
Severe lesions of fingertips and paronychia resulted 
in discontinuation of therapy in one case. Antiseptics, 
oral or topical antibiotics and, in severe cases, ste-
roids are helpful in the treatment of paronychia. The 
route of administration of antibiotics depends on the 
severity of lesion (9,26).
Hair changes can be also observed during cetux-
imab therapy. Significant trichomegaly is an example 
(not graded according to CTCAE v. 4.0). It manifests 
in long and rigid, sometimes curly lashes (Figure 4). 
It appeared in five cases during our study. This is a 
typical side effect of EGFR inhibitor therapy (27). Tri-
chomegaly in combination with xerophthalmia can 
cause bilateral ocular discomfort, foreign body sensa-
tion and tearing. In some cases, it may impair vision. 
If the eyelashes become too long and start to irritate 
the surface of the eye, they should be cut (28). Anoth-
er side effect concerning hair – hypertrichosis – was 
noticed in one of our patients treated with cetuximab 
(Figure 5). Alopecia was also observed among our 
patients. However, due to insufficient data in patient 
records, it was impossible to estimate the frequency 
and severity of alopecia in our population. Loss of 
hair can occur on the scalp and extremities, whereas 
hypertrichosis appears on the back, on female lips, 
and on the face (16). These changes suggest that the 
mechanism regulating hair growth may vary in differ-
ent parts of the body.    
Serious allergic reactions are observed in 2.8-7.5% 
of patients according to the literature data (3,11-15), 
which is in agreement with the results of our study 
(7%). In three of our patients, severe infusion reac-
tions from cetuximab appeared after the first dose. 
Severe infusion reactions are a contraindication for 
the continuation of cetuximab therapy (29).
Analysis by Jatoi et al. shows correlation between 
the sex and age of patients and the severity of the 
rash during cetuximab therapy. In their study, more 
Figure 5. Hipertrichosis.
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men than women developed rash in Grade 3: 34 (7%) 
versus 16 (3%) (multivariate odds ratio 2.12; P=0.017). 
Grade 3 rash also occurred in younger patients (<70 
years of age): 48 (6%) versus 2 (1%) (multivariate odds 
ratio 0.21; P=0.032). In contrast to the literature, in our 
group older patients were at greater risk of rash in 
Grade 3: 2 (5.4%) after 55 years of age versus 1 (2.7%) 
before 55 years of age. All Grade 3 rashes developed 
in men: 3 (8.1%), all women suffered from rash in G1 
or G2. It should be noted that our results are not pre-
dictive (odds ratio for age and gender P=0.3086 and 
P=0.7689, respectively). It is likely that the absence 
of a statistically significant association between the 
presence of rash and age or gender was caused by 
the small number of patients in the study. It is pos-
sible that correlation exists and may be observed in 
larger groups of patients.
This study has some limitations as a result of its 
retrospective nature and the group size. Patient data 
and their treatment histories were gathered from 
medical records. Occasionally, information about 
adverse effects was incomplete (e.g. lack of informa-
tion about the severity of the symptom). When any 
concern about the patient history occurred, it was 
discussed with the oncologist treating the patient. 
It is important to note that in order to provide suf-
ficient and timely dermatological treatment for such 
patients, the oncologists should be more attentive in 
description of side effects. Moreover, adverse effects 
which occur rarely should be described in detail. The 
statistical analysis that was performed is not predic-
tive on grounds of the wide variety and small number 
of patients in the study.
This study shows that cetuximab-related adverse 
effects present their specific features regardless of 
the concomitant chemotherapy. Knowing the main 
symptoms of possible adverse effect allows the safety 
of the therapy to be monitored and early treatment 
of skin lesions, before they cause the treatment to be 
discontinued. 
ConClUSIon
Therapy with mAbs is characterized by a specific 
profile of adverse effects which affect the skin and 
appendages especially. These side effects are usually 
not life-threatening, but if severe can require cessa-
tion or temporary termination of therapy. Moreover, 
skin lesions can bring on social or emotional anxiety. 
Therefore, it is important to prevent such skin toxici-
ties through proper care and early cooperation be-
tween the oncologist and dermatologist.
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